Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.44 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4898763 | 0.96 | GPR119 (0.46) | NPC1RAB9AGPR119TP53ESR2 | |
| SCHEMBL4898897 | 0.89 | USP30 (0.46) | NPC1RAB9AGPR119ESR2 | |
| SCHEMBL5254230 | 0.84 | TP53 (0.53) | NPC1RAB9AGPR119TP53 | |
| SCHEMBL5256365 | 0.83 | STS (0.47) | GPR119TP53ESR2 | |
| SCHEMBL30568000 | 0.83 | STS (0.47) | GPR119TP53ESR2 | |
| SCHEMBL2774721 | 0.83 | SMN1; SMN2 (0.49) | GPR119TP53 | |
| SCHEMBL4114089 | 0.83 | NR1H2 (0.59) | NPC1RAB9AGPR119TP53ESR2 | |
| SCHEMBL2709205 | 0.83 | FPR2 (0.51) | NPC1RAB9AGPR119TP53ESR2 | |
| SCHEMBL26916123 | 0.82 | HTR2C (0.48) | HCAR1NPC1RAB9AGPR119TP53 | |
| SCHEMBL26916056 | 0.82 | HTR2C (0.48) | HCAR1NPC1RAB9AGPR119TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318933-A1 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | GLAXO GROUP LIMITED | 2008-12-25 | — | — | US | disclosed |
| EP-1814873-A2 | 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2007-08-08 | — | — | EP | disclosed |
| WO-2006038006-A2 | 5-SULFONYL-1-PIPERIDINYL SUBSTITUTED INDOLE DERIVATIVES AS 5-HT6 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF CNS DISORDERS | GLAXO GROUP LIMITED (GB) | 2006-04-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318933-A1 | 5-Sulfonyl-1-Piperidinyl Substituted Indole Derivatives as 5-Ht6 Receptor Antagonists for the Treatment of Cns Disorders | HTR6, HTR5A, TPH1 | HCAR1 172/4885NPC1 818/4885RAB9A 2312/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.